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Antigen specific suppressor cell activity of peripheral 
blood mononuclear cells was investigated in 20 patients 
with psoriatic arthritis and 18 patients with uncompli-
cated p soriasis and compared to that of 27 age- and sex-
matched healthy controls and 18 patients with osteoar-
thritis. Topical skin therapy and nonsteroidal anti-in-
flammatory medications were allowed but patients who 
had taken disease suppressive, immunosuppressive, cy-
totoxic, and systemic steroid therapy were exclud ed. 
The r esults demonstrate reduced suppressor cell activ-
ity (SeA) in patients with psoriatic arthritis compared 
to normal controls (54.8% ± 4.9 vs 68.4 ± 2.8, P <0.005). 
Similarly, the response of patients with uncomplicated 
psoriasis was significantly lower than normal (50.1 ± 4 .9 
vs 67.3 ± 3.0% p < 0.005). Five of the 20 patients with 
p soriatic arthritis and 7 of the 18 patients with uncom-
plicated psoriasis demonstrated SeA of more than 2 SD 
below the normal m ean. 
The SeA of patients with osteoarthritis was normal. 
The plaque forming cell (PFC) response of patients with 
p soriatic arthritis and uncomplicated psoriasis was not 
diffe r ent from those of the normal controls or of patients 
with osteoarthritis. There was no correlation between 
impaired s uppression and disease activity or therapy. 
Psorias is is a chronic skin disorder that affects 1-3% of the 
general population ll]. Up to 30% of t he patients with psoriasis 
may have an associated seronegative arthri tis [2,3]. The etiol-
ogy of psoriasis a nd psoriatic arthri t is remains u'nclear. Recent 
evidence suggests t hat immune m echanisms contribute at least 
in part to the t issue injury in t his disease [4]. Thus, a hyper-
active humora l, or B cell response has been demonstrated in 
association with impaired T cell function [5]. It has been 
suggested t hat the humoral immune abberations described in 
psoriatic patients may result from a loss of T regulatory (sup-
pressor) cells [6]. This concept is supported by studies in auto-
immune diseases in which hyperactive B cell fun ction is asso-
ciated with defective T suppressor cell activity. We have pre-
viously demonstrated impaired suppressor cell activity in pa-
tients with systemic lupus erythematosus and rheumatoid a r-
thri t is [7,8]. In both th ese disorders a defect in suppressor cell 
fun ction has been postulated as contributing to a utoantibody 
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formation, R ecently, impaired suppressor cell function was 
demonstrated in patients with cutaneous psoriasis [9,10]. W e 
therefore studied suppressor cell function in patients with c u-
taneous psoriasis and in patients with psoriatic arthri t is, using 
an antigen specific suppressor cell assay (11). Ow- s tudy dem-
onstrates impaired a ntigen specific suppressor cell activity in 
som e patients with psoriasis and psoriatic arthritis relative to 
healthy controls a nd patients with osteoarthrit is. 
MATERIALS AND METHODS 
Patient Popula.tions 
Psoriasis: 18 patients with cutaneous psoriasis, uncomplicated by 
arthritis, who were attending the Psoriasis Education and Resear ch 
Center (PERC), Women's College Hospital, Toronto, were studied 
(Table). There were 12 females and 6 males with a mean age of 40 Y1' 
and a mean disease duration of 14.4 yr. None had taken systemic 
steroids, methotrexate, PUVA, or Retinoid therapy. Skin assessmen ts 
were performed by a dermatologist according to a standru'd protocol 
and expressed as percent skin involvement. 
Psoriatic arthritis: 20 patients attending the Psoriatic Arthritis 
Clinic and PERC, Women's College Hospital, were studied. There were 
12 males and 8 females with a mea n age of 52 yr and a mean disease 
duration of 15.7 yr for skin disease and 10.8 yr for joint disease (Table). 
None of the patients had taken systemic steroids, disease suppressive 
(gold, chloroquine, penicillamine) , or cytotoxic therapy (lmuran, meth-
otrexate or PUVA) , nor Retinoid therapy prior to the study. Medica-
tions taken at the time of the study are listed in the Table. Skin disease 
was assessed by a dermatologist as above, and joint involvement was 
recorded by a rheumatologist according to the number of actively 
inflammed joints (stress pain, tenderness, effusion) and articulru' index. 
All patients had peripheral joint involvement- while 6 had both pe-
ripheral and axial joint disease. 
Contro ls 
(a) Healthy volunteers (hospital personnel) age- and sex-matched to 
the patients constituted the normal controls. (b) Eighteen patients wi th 
radiologically defined erosive osteoru·thri tis were also studied. There 
were 14 females and 4 males with a mean age of 63 yl". All were taking 
nonsteroidal anti-inflammatory medications at the t ime of the study. 
Cell Sepa.ration 
Periphera l blood mononuclear ce lls (PBM) were isolated by Ficoll-
Hypaque gradient centrifugation [1 2]. T he cells were then washed 
twice with phosphate buffered saline (PBS), pH 7.4 and resuspended in 
RPMI 1640 (Gibco, Grand Island, New York) , supplemented with alpha 
glu tamine (2 mM), 2-mercaptoethanol (5 x 10-" M) penicillin (100 u/ 
ml) , streptomycin (10 I-'g/ mi) and 10% heat- inactivated normal human 
serum. 
406 
An.tigen 
Crystalline ovalbumin (OA) (Sigma Chemical Company, St. Louis, 
Missouri) was prepared as a stock solu tion (J mg/ ml) in PBS and 
stored at -20°C. Sheep red blood cells (SRBC) (Woodlyn Fru'ms, 
Guelph , Ontario) were washed 3 times before use. 
Complement 
Commercially ava ilable guinea pig complement (Gibco, USA) was 
reconstituted and absorbed 3 times with SRBC. 
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Number of patients 
Male/female 
Mean Age in years (range) 
Mean Disease Duration 
Skin (range) 
Joints (range) 
Number untreated 
Topical agents 
Tar 
Steroid cream 
UVE light 
Antirheumatic medications 
Enteric coated ASA 
Indocid 
Othe r nonsteroidal 
Clinical data 
Psoriasis 
18 
6/ 12 
40(21-76) 
14.4(1-39) 
8 
11 
6 
11 
Plague Forming Cell (PFC) R esponse 
Pso riati c arthri tis 
20 
12/8 
52(24-70) 
15.7 (3-40) 
10.8(0.2-35) 
8 Skin 
5 Joints 
12 
3 
7 
15 
9 
3 
3 
PFC were induced and evaluated according to the method of Dosch 
and Gelfand as previously described [II). Ten ml target cultures were 
set up in 17 X 100 mm plastic t issue culture tubes containing 2 X lOG 
fresh PBM with 10 p.g OA (optimal for PFC generation) in supple· 
mented RPMI 1640 media. After 6 days in moist 5% CO2 at 37° 
inc ubation the target cultures were washed twice and assayed in trip-
licat e for PFC. Less than 200 plaques per 10'; lymphocytes were consid-
ered background. 
Generation of Suppressor Cells and Suppressor Cell Assay 
Suppressor cells were generated by incubating 2 X 10'; fresh PBM 
with 100 p.g of OA. Control cells were incubated without ~A . After 24 
hr t h e cells were harvested, washed twice with RPMI 1640, and resus-
pended at a concentration of 1 x 10" cell/ ml. Cell viability and recovery 
of the OA-primed cultUl'es were comparable to control (un primed) 
cultures. One million viable OA-primed or control cells were added to 
a target culture of 2 x lOr; fresh autologous cells. The mixture was 
cultured with 10 p.g of OA for 6 days at 37°C, hal'vested and assayed 
for direct anti-OA PFC as described. Suppression was expressed as 
[ 
PFC(P)] 1 - PFC(C) x 100% suppression, where PFC(P) was the PFC re-
sponse when primed cells were added and PFC (C) the response when 
unpriIned (control) cells were added to the target cultures. 
Statistical Methods 
Student t-test was used to compare the degree of suppression be-
tween patient and control groups. A regression analysis was used for 
correlations between degree of suppression and disease activity and 
between PFC response and disease activity [13]. 
RESULTS 
The in vitro plaq ue cell response to ovalbumin was fU'st 
examined. Lymphocytes from patients with psoriasis exhibited 
a higher PFC response than the matched controls, but the 
difference was not statistically significant (Fig lA). The in vitro 
plaque response of patients with psoriatic arthritis was not 
different from normal controls or patients with osteoarthritis 
(Fig IB and C). Suppressor cell activity of the 18 patients with 
cutaneous psoriasis was compared to that of 14 age and sex 
matched normal controls (Fig 2A). The results demonstrated 
s ignificantly reduced suppression in the patients (50.1 ± 4.9% 
vs 67.3 ± 3.0%, p < 0.005). Seven of the 18 patients 01' 39.9% 
demonstrated suppression of less t han 2 SD below the normal 
mean. 
Similarly, 20 patients with psoriatic arthritis demonstrated 
significantly reduced suppressor cell activity when compared to 
12 age and sex matched controls (Fig 2B). (54.8% ± 4.9 vs 68.5 
± 2.8%, p < 0.005). Five of the 20 patients (25%) demonstrated 
suppression of less than 2 SD below the normal mean. . 
The antigen specific suppressor cell activity observed m 
patients with osteoarthritis was not different from that of 
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FIG l. Plaque form ing cells (PFC) responses of opti mally primed 
(10 p.gin crystalline ovalbumin/ culture) target cultures in patients (e ) 
and controls. (0 ). Each point represents the mean PFC response of 
trip licate cultures. Mean PFC response is depict.ed by (X) and elTor 
bru's represent ± 1 SE (-) and ± 1 SD (-). A, uncomplicated psoriasis: 
B, psoriatic arthritis; and C, osteoalthritis. 
normal controls (64.9 ± 3.4% vs. 66.6 ± 2.7%; F ig 2C). There 
was no correlation between PFC responses and suppressor cell 
activity. 
The impaired suppressor cell activity observed in patients 
with psoriasis and psoriatic ruthritis did not correlate with 
e ither extent of skin disease or with t he degree of jo in t involve-
ment. There was no relationship between the degree of sup-
pre'ssion and the patte rn or duration of t h e skin 01' joint disease. 
DISCUSSION 
It has been suggested that a defective cellular immune re-
sponse may lead to the development of psoriasis [4]. Immuno-
logical abnormalities have indeed been reported in patients 
with cutaneous psoriasis and in pa tients wi t h psoriat ic arthritis 
[4-6, 14-20]. These patients have demonstrated a hyperactive 
B cell response manifested by increased levels of immunoglob-
ulins, pruticulru'ly of IgG a nd IgA classes [14-20]. Recently, 
circula ting immune complexes have been detected in t he sera 
of patients with cutaneous psorias is a nd psoria tic a r thJ'i t is 
[5,16 ,21]' In vitro studies of T cell-mediated immune functions 
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FIG 2. S uppressor ce ll activity in patients and con trol . Each point 
rep resents percent suppression fo r the individua l patien t (e) or con trol 
(0 ). Mean percent suppression fo r each group is shown (X) and the 
error bars ind ica te ± 1 SE (-) and 1 ± SD (-). A , uncomplicated 
psoriasis; B, psoriatic arth rit is; and C, osteoarthritis . . 
have shown diminished response to Concanavalin A in some 
but not all patients with psoriasis with or wi thout ar thri t is [12-
16]. Defective immunoregulatory cell activity has recently been 
reported in patients wi th psoriasis. Sauder et al [9], using 
Concanavalin to induce suppression of mitogen responsiveness 
. demonstrated a marked impairment in suppressor cell activity 
in 10 patients with extensive cutaneous psoriasis. H unyadi et al 
[10] using a similar assay showed impaired suppression in a 
group of 25 patients with psoriasis vulgaris. In the present 
study, an ant igen specific suppressor cell system was used, in 
which T suppressor cell activity was generated with high dose 
antigen (OA) to suppress the in vitro antibody response to the 
specific a ntigen [11]. We have demonstrated impai.red suppres-
sor cell activity in some patients wit h psoriasis and psoriatic 
ar thr it is. 
In contrast, patients with osteoarthrit is, in whom no immu-
nologic abnormalit ies have been reported, demonstrated nor-
mal suppression. T his is despi te the fact that patients wi th 
osteoarthri t is were older than our patients with psoriasis, with 
or without arthri tis, and migh t have been expected to show 
impaired suppression as a consequence of age [22]. 
T he mechanism responsible for t he impaired suppression 
remains unclear. One possibili ty may be a reduction in the 
nu mber of T cells subserving immunoregulation. T his is sup-
Vol. 77, No.5 
ported by data dem onstrating a reduction in t he num ber of T 
cells both in patients with cutan eous psoriasis and patients with 
psoriatic ar thri tis [16,17,19]. Moreover , a reduction in the num-
ber of T cells bearing receptors for the Fc por tion of IgG (T y 
cells) thought to contain suppressor cell activity has recently 
been demonstrated in patients wi th psoriatic ar thri t is [16]. 
Other mechanisms migh t account for the impaired suppressor 
cell activity observed in these patients. T he nonsteroidal ant i-
inflammatory therapy might have contributed to the observa-
t ions, but there was no constant relationship between the 
therapy taken and the suppressor activity. M oreover, patients 
with osteoar thrit is receiving similar medications exhibi ted nor-
mal suppression. S imilarly, although ultraviolet light has been 
shown to alter lymphocyte function [23] , no correlation between 
SCA activity and UV -ligh t therapy could be demonstrated. 
Steroids absorbed from topical application migh t have caused 
impaired suppression . H owever, there was no correlation be-
tween SCA and eit her use of topical steroids or extent of skin 
involvement. 
Excessive T- helper or intrinsic B cell reactivity might ac-
count for the observations. The magni tude of the in vi tro P FC 
response is the result of a balance of helper and suppressor 
activity upon an ant igen activated B cell. Indirect evidence has 
suggested a normal B cell populat ion in pa tients with psoriasis 
and psoriatic arthrit is . Normal B cell numbers have been noted 
in these patients and a normal response to Pokeweed mitogen 
(a T and B cell mi togen) have been reported [16,17]. M oreover , 
the plaque-forming cell response in the present study was 
essentially normal. T o date, studies of helper T cell activity 
have not been reported. Further studies ar e clearly indicated to 
elucida te the mechanism of impaired suppression . 
Al t hough impaired suppressor cell activity has been demon-
strated in the present study, only a portion of the patients 
exhibi ted a profound immunoregulato ry a bnormality. Thus it 
is conceivable that subsets of patients may be defined with 
differ ent immune a bnormalities. The lack of correlation wi th 
the magnit ude of skin and joint involvement suggests that in 
the majority of patients with cutaneous psoriasis and psoriatic 
ar t hrit is addit ional mechanisms other than defective suppressor 
cell activity account fOl" the humoral immune abbera tions ob-
served. 
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Announcement 
An international workshop on "Cell Proliferation in Psoriasis" devoted to the analysis of methodology 
and kinetic and biochemical mechanisms in proliferative skin disease, and to the exploitation of cell 
kinetics in the chemotherapy of psoriasis, will be held in Oxford, April 5-7, 1982, Further details are 
available from Professor N. A. Wright, Department of Histopathology, Royal Postgraduate Medical 
School, Ducane Road, London W12 ORS. 
